A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials

A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials

IntroductionImmunotherapy is an effective treatment for a subset of cancer patients, and expanding the benefits of immunotherapy to all cancer patients will require predictive biomarkers of response and immune-related adverse events (irAEs). To support correlative studies in immunotherapy clinical t...

Full description

Bibliographic Details
Main Authors: Jeffrey R. Whiteaker, Lei Zhao, Regine M. Schoenherr, Dongqing Huang, Rachel A. Lundeen, Ulianna Voytovich, Jacob J. Kennedy, Richard G. Ivey, Chenwei Lin, Oscar D. Murillo, Travis D. Lorentzen, Simona Colantonio, Tessa W. Caceres, Rhonda R. Roberts, Joseph G. Knotts, Joshua J. Reading, Candice D. Perry, Christopher W. Richardson, Sandra S. Garcia-Buntley, William Bocik, Stephen M. Hewitt, Shrabanti Chowdhury, Jackie Vandermeer, Stephen D. Smith, Ajay K. Gopal, Nirasha Ramchurren, Steven P. Fling, Pei Wang, Amanda G. Paulovich
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
correlative biomarkers
immunotherapy
immuno-oncology
immuno-MRM
proteomics
targeted proteomics
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1168710/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1168710/full

Similar Items